
Day 1 - August 16th – Monday
PJ1
POPULATION PHARMACOKINETIC ANALYSIS TO INVESTIGATE CETIRIZINE X GABAPENTIN INTERACTION IN PATIENTS WITH NEUROPATHIC PAIN
PJ10
DEVELOPMENT AND VALIDATION OF A MICROSAMPLING STRATEGY TO OPTIMIZE ANTITUBERCULOSIS THERAPY
PJ11
EVALUATION OF PHARMACOKINETICS OF α-BISABOLOL AND HECOGENIN ACETATE FREE AND COMPLEDEX WITH β-CYCLODEXTRIN
PJ12
CLINICAL, GENETIC AND NUTRITIONAL FACTORS ASSOCIATED WITH INR: INFLUENCE OF WARFARIN AND ITS HYDROXYLATED METABOLITE PLASMA CONCENTRATIONS IN PATIENTS UNDERGOING ANTICOAGULATION THERAPY
RP11
POPULATION PHARMACOKINETICS OF TENOFOVIR/EMTRICITABINE AMONG TRANSWOMEN AT HIV RISK ON ORAL PREP AND FEMINIZING HORMONE THERAPY: ANALYSIS OF POTENTIAL INTERACTIONS
TC1
A QSP MODEL CHARACTERIZING VALPROIC ACID -INDUCED HYPERAMMONEMIA AND THE IMPACT OF CARNITINE SUPPLEMENTATION
TC11
EFFECT OF TEMPERATURE AND ADMINISTRATION ROUTE ON THE BIOAVAILABILITY OF FLORFENICOL IN RUSSIAN STURGEONS (Acipenser gueldenstaedtii)
Day 2 - August 17th - Tuesday
PJ14
POPULATION PHARMACOKINETIC MODELING OF FLUOXETINE IN RATS TO DETERMINATE DIFFERENCES AMONG INDIVIDUALS CLASSIFIED ACCORDING TO THEIR PLASMA SEX HORMONES
PJ15
POPULATION PHARMACOKINETIC MODELING IN RATS OF ISOQUERCETIN PRESENT IN Passiflora ligularis EXTRACT - LOADED SELF-EMULSIFYING SYSTEM
PJ16
PHARMACOGENETIC AND PHARMACOKINETIC STUDY OF CARIBBEAN HISPANICS TREATED WITH BUPRENORPHINE
PJ17
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING APPLIED TO CHILD SAFETY AND RISK ASSESSMENTS: SODIUM VALPROATE
RP13
PHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING TO PREDICT OMEPRAZOLE BIOAVAILABILITY FROM ENTERIC-COATED MICROGRANULES
RP14
APPLIED CONCEPTS IN PBPK MODELING IN PhysPK: DISSOLUTION, ABSORPTION, INTESTINAL TRANSIT AND PH EFFECT
RP15
POPULATION PHARMACOKINETIC MODEL OF METHOTREXATE IN BRAZILIAN PEDIATRIC PATIENTS WITH ACUTE LIMPHOBLASTIC LEUKEMIA
RP16
POPULATION PHARMACOKINETIC MODEL OF CIPROFLOXACIN LUNG AND EPITHELIAL LINING FLUID DISTRIBUTION IN DIFFERENT STAGES OF Pseudomonas aeruginosa LUNG INFECTION IN RODENTS
RP17
A JOINT PARENT-METABOLITE MODEL TO CHARACTERIZE SEX-RELATED DIFFERENCES OBSERVED IN LEVODOPA AND 3-O-METHYLDOPA PHARMACOKINETICS IN HEALTHY SUBJECTS
TC12
DESIGN OF A STRATEGY TO OPTIMIZE ANTIBIOTIC TREATMENT WITH PIPERACILLIN/TAZOBACTAM IN NEONATES WITH SEVERE INFECTIONS USING A POPULATION-BASED APPROACH
TC13
COMPARATIVE ANALYSIS OF BAYESIAN CLINICAL DECISION SUPPORT SOFTWARE OF VANCOMYCIN DOSING (DoseMeRx®) VERSUS CLINICIAN GUIDED VANCOMYCIN DOSING IN AN INPATIENT POPULATION
TC14
DOWN-REGULATION OF TESTOSTERONE IN PIGS AFTER SUSTAINED-RELEASE SUBCUTANEOUS ADMINISTRATION OF A SINGLE DOSE OF 4.7 MG OF DESLORELIN
Day 3 - August 18th - Wednesday
PJ18
A SEMI-MECHANISTIC PBPK MODEL FOR VORICONAZOLE BRAIN DISTRIBUTION IN RATS AS A TOOL TO PREDICT BRAIN LEVELS EXPOSURE IN HUMANS WITH MENINGITES
PJ3
INTEGRATING STATISTICAL AND MECHANISTIC MODELING TO EXPLAIN INTRA-INDIVIDUAL VARIABILITY IN DRUG BIOEQUIVALENCE STUDIES: A PATH TO VIRTUAL BIOEQUIVALENCE
RP19
POPULATION PHARMACOKINETIC OF 1B8 MONOCLONAL ANTIBODY IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
RP7
PK AND PD CHARACTERIZATION OF WARFARIN RESPONSE IN PUERTO RICAN PATIENTS BASED ON INDIVIDUAL GENOTYPES
TC3
POPULATION PHARMACOKINETICS/PHARMACODYNAMICS MODELING OF CLOZAPINE-LOADED NANOCAPSULES IN RATS
TC4
DEVELOPMENT OF A PHARMACOKINETIC MODEL BASED ON PHYSIOLOGY (PBPK) TO EVALUATE THE DRUG PHARMACOKINETIC INTERACTION BETWEEN BUPROPIONA AND RIFAMPICIN IN PATIENTS WITH TUBERCULOSIS
Day 4 - August 19th - Thursday
PJ4
PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF FUNGISTATIC EFFECT OF AMPHOTERICIN B AGAINST Candida albicans
PJ6
PHYSIOLOGY-BASED PHARMACOKINETIC (PBPK) MODELING OF METHYLPHENIDATE FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS
RP3
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL OF CARVEDILOL IN PATIENTS BEFORE AND AFTER ROUX-EN-Y GASTRIC BYPASS SURGERY
RP4
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF HIDROXICHLOROQUINE ENANTIOMERS IN HEALTHY VOLUNTEERS
RP5
PHARMACOLOGICAL INTERACTIONS OF MONOTERPENES AND IN VIVO EVALUATION OF THEIR NEMATODICIDAL ACTIVITY
RP6
POPULATION PHARMACOKINETIC MODELLING OF TOBRAMYCIN LUNG AND EPITHELIAL LINING FLUID ALTERED DISPOSITION DUE TO BIOFILM-FORMING Pseudomonas aeruginosa INFECTION
TC5
CEFTAROLINE POPULATION PHARMACOKINETIC MODEL CHARACTERIZING DISTRIBUTION TO MUSCLE AND SUBCUTANEOUS TISSUES OF HEALTHY VOLUNTEERS AND CEREBROSPINAL FLUID OF NEUROSURGICAL PATIENTS
Day 5 - August 20th - Friday
PJ8
IMPLEMENTATION OF A PILOT THERAPEUTIC DRUG MONITORING PROGRAM FOR ANTIBIOTICS IN PEDIATRIC PATIENTS
PJ9
VALIDATION METHOD ANALYTICAL BY UPLC-MSMS FOR SIMULTANEOUS QUANTIFICATION OF LAMOTRIGINE, CARBAMAZEPINE, TOPIRAMATE, LEVETIRACETAM
RP8
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL TO ASSESS POTENCIAL DISEASE-DRUG-DRUG INTERACTIONS WITH REMDESIVIR
TC7
DESCRIPTIVE POPULATION MODELING OF MATRIX EFFECTS OF AN EXTRACT OF CALYCES FROM Physalis Peruviana L. ON RUTIN PHARMACOKINETICS IN WISTAR RATS
TC8
MODEL-BASED BIOEQUIVALENCE ANALYSIS TO ASSESS AND PREDICT THE RELATIVE BIOAVAILABILITY OF VALPROIC ACID FORMULATIONS
TC9
PERFORMANCE EVALUATION OF A PRECISION DOSING SERVICE FOR VANCOMYCIN IN A TERTIARY LEVEL PEDIATRIC HOSPITAL

